8:00 - 8:30 am: Registration and breakfast 8:30 am: Welcome - Dr. Jeff Trent, President and Research Director, Van Andel Research Institute
- Dr. Jim Fahner, Division Chief, Pediatric Hematology/Oncology, Helen DeVos Children’s Hospital
8:45 am: Pat Lacey, Advocate, Friends of Will ~ Milestones 8:55 am: Agenda Review ~ Dr. Giselle Sholler and Dr. Craig Webb, Van Andel Research Institute Session 1: Personalized Medicine Advances9:00 - 9:30 am: Dr. Sholler and Dr. Webb ~ Progress Report on NMTRC Genomics Trials for Personalized Treatment of Neuroblastoma 9:30 - 9:50 am: Dr. David Craig, Translational Genomics Research Institute ~ Clinical Uses Of Next Generation Sequencing 9:50 - 10:10 am: Dr. Jason Glover, Oregon Health Sciences University ~ Exploring novel kinase targets in neuroblastoma using small molecule inhibitor panels 10:10 - 10:30 am: Dr. Carol Thiele, National Cancer Institute, NIH ~ Epigenetics of Neuroblastoma 10:30 - 10:45 am: Break Session 2: Early Phase Clinical Trials in Neuroblastoma10:45 - 11:05 am: Dr. William Ferguson, St. Louis University ~ Nifurtimox Study Update 11:05 - 11:25 am: Dr. Don Eslin, MD Anderson Orlando ~ Review of the Phase I trial and overview of the upcoming Phase II trials with TPI 287 11:25 - 11:45 am: Dr. Andre Bachmann, University of Hawaii ~ DFMO/Eflornithine: A FDA-approved Trypanosoma Drug with a New Purpose in the Treatment of Neuroblastoma 11:45 am - 12:05 pm: Dr. Melinda Merchant, National Cancer Institute, NIH ~ Immune checkpoint inhibition: An update from the ongoing Pediatric Phase I trial of ipilimumab (Yervoy) 12:05 - 1:00 pm: Lunch 1:00 - 2:00 pm: Keynote – Dr. David Krag, University of Vermont ~ Customized antibodies for treatment of neuroblastoma Session 3: Neuroblastoma Translational Research2:00 - 2:20 pm: Dr. Rae Nishi, University of Vermont ~ Nicotinic Receptors and Neuroblastoma: a New Therapeutic Target 2:20 - 2:40 pm: Pamela Lescault, University of Vermont ~ Genomic expression of neuroblastoma in the bone marrow 2:40 - 3:00 pm: Dr. Jacqueline Kraveka, South Carolina Medical Center ~ Bioactive Sphingolipids in Neuroblastoma 3:00 - 3:15 pm: Break Session 4: Partnering to bring therapies to children3:15 - 3:30 pm: Dr. Steve Weitman, University of Texas Health Science Center San Antonio ~ Drug approval path in Pediatric Oncology 3:30 to 3:45 pm: Nancy Goodman, Founder and Executive Director of Kids v Cancer ~ Creating Hope Act 3:45 - 4:00 pm: Tom Dunbar, Past Chair of the Board of Trustees of CureSearch National Childhood Cancer Foundation ~ Childhood advocacy experience 4:00 - 4:15 pm: Jeff Jacob, President, Cancer Prevention Pharmaceuticals ~ Bringing therapies to children with orphan disease: A team approach 4:15 - 4:45 pm: Panel Discussion 4:45 - 4:55 pm: Andy Mikulak, Advocate, Max's Ring of Fire ~ A Parent’s Perspective 4:55 - 5:00 pm: Closing Remarks | 
